Encainide (HCl)
Generic medicine reference
Not yet clinically reviewed
This entry was migrated from the earlier Pharmapedia app bundle and has not been reviewed by a named clinician on this site. It is provided for educational reference only — verify dosage and safety information against current, authoritative sources and a qualified healthcare professional before any clinical use.
Overview
Encainide (HCl) is antiarrhythmic agent. Encainide (HCl) is investigational drug. Encainide (HCl) is used to treat irregular heartbeats (arrhythmias) and maintain a normal heart rate.
Indications
Encainide (HCl) is primarily indicated in conditions like Cardiac arrhythmia, Supraventricular arrhythmias, Ventricular arrhythmias.
Contraindications
Encainide (HCl) is contraindicated in conditions like Cardiogenic shock, Cardiac failure, Conduction system disease.
Side Effects
The severe or irreversible adverse effects of Encainide (HCl), which give rise to further complications include Congestive heart failure, Sinoatrial block. Encainide (HCl) produces potentially life-threatening effects which include Arrhythmias, which are responsible for the discontinuation of Encainide (HCl) therapy. The signs and symptoms that are produced after the acute over dosage of Encainide (HCl) include Bradycardia, Hypotension, Cardiogenic shock, Asystole, Torsades de pointes, AV block.The symptomatic adverse reactions produced by Encainide (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Nausea, Vomiting, Dyspnea, Insomnia, Tinnitus, Blurred vision, Metallic taste.
Warnings
It should be used with caution in patients with a history of a myocardial infarction with left ventriuclar dysfunction because of an increased risk of arrhythmias. Electrolyte imbalances, such as hyperkalemia or hypokalemia, should be corrected before beginning therapy with any antiarrhythmic agent. It should be used with caution in patients with diabetes mellitus or pre-existing glucose-intolerance. Blood glucose monitioring is recommended. Encainide should be used with caution in patients with kidney or liver impairment, because hepatic impairment may reduced elimination rate of encainide which may lead to toxicity.
High Risk Groups
Drug should not be given to Pregnant Mothers, and Neonates. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Adult Dosage
0.357 mg/kg (0.36 (0.357)) 8 hourly PO — Initially for 1 Week
0.5 to 0.714 mg/kg (0.61 (0.607)) 8 hourly PO — Maintenance, As Required
Child Dosage
No child dosage information is recorded for this medicine yet.
Neonatal Dosage
No neonatal dosage information is recorded for this medicine yet.
Drug Interactions
Encainide (HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementCimetidine (HCl)Paroxetine These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Storage
Caps Store Below 40°C. Protect from Moisture and Heat.
Available Brands in Pakistan
No brands are recorded for this generic.